You are here

Article Text

Article menu

Download PDFPDF

Chronic obstructive pulmonary disease
Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease
Free
  1. J P Fuld1,2,
  2. L P Kilduff1,3,
  3. J A Neder1,
  4. Y Pitsiladis1,
  5. M E J Lean4,
  6. S A Ward1,5,
  7. M M Cotton2
  1. 1Centre for Exercise Science and Medicine, Institute of Biological and Life Sciences, University of Glasgow, Glasgow, UK
  2. 2Department of Respiratory Medicine, Glasgow Royal Infirmary, Glasgow, UK
  3. 3Department of Sports Science, University of Wales, Swansea, UK
  4. 4Department of Human Nutrition, University of Glasgow, Glasgow, UK
  5. 5School of Sport and Exercise Sciences, University of Leeds, Leeds, UK
  1. Correspondence to:
    Dr J P Fuld
    Department of Cystic Fibrosis and Lung Defence, Papworth Hospital, Papworth Everard, Cambridgeshire CB3 8RE, UK; j.fulddsl.pipex.com

Abstract

Background: Skeletal muscle wasting and dysfunction are strong independent predictors of mortality in patients with chronic obstructive pulmonary disease (COPD). Creatine nutritional supplementation produces increased muscle mass and exercise performance in health. A controlled study was performed to look for similar effects in 38 patients with COPD.

Methods: Thirty eight patients with COPD (mean (SD) forced expiratory volume in 1 second (FEV1) 46 (15)% predicted) were randomised to receive placebo (glucose polymer 40.7 g) or creatine (creatine monohydrate 5.7 g, glucose 35 g) supplements in a double blind trial. After 2 weeks loading (one dose three times daily), patients participated in an outpatient pulmonary rehabilitation programme combined with maintenance (once daily) supplementation. Pulmonary function, body composition, and exercise performance (peripheral muscle strength and endurance, shuttle walking, cycle ergometry) took place at baseline (n = 38), post loading (n = 36), and post rehabilitation (n = 25).

Results: No difference was found in whole body exercise performance between the groups: for example, incremental shuttle walk distance mean −23.1 m (95% CI −71.7 to 25.5) post loading and −21.5 m (95% CI −90.6 to 47.7) post rehabilitation. Creatine increased fat-free mass by 1.09 kg (95% CI 0.43 to 1.74) post loading and 1.62 kg (95% CI 0.47 to 2.77) post rehabilitation. Peripheral muscle performance improved: knee extensor strength 4.2 N.m (95% CI 1.4 to 7.1) and endurance 411.1 J (95% CI 129.9 to 692.4) post loading, knee extensor strength 7.3 N.m (95% CI 0.69 to 13.92) and endurance 854.3 J (95% CI 131.3 to 1577.4) post rehabilitation. Creatine improved health status between baseline and post rehabilitation (St George’s Respiratory Questionnaire total score −7.7 (95% CI −14.9 to −0.5)).

Conclusions: Creatine supplementation led to increases in fat-free mass, peripheral muscle strength and endurance, health status, but not exercise capacity. Creatine may constitute a new ergogenic treatment in COPD.

  • BMI, body mass index
  • CWR, constant work rate exercise test
  • ESWT, endurance shuttle walk test
  • FEV1, forced expiratory volume in 1 second
  • FFM, fat-free mass, FM, fat mass
  • FVC, forced vital capacity
  • IET, incremental exercise test
  • ISWT, incremental shuttle walk test
  • MIP, maximum inspiratory pressure
  • MVV, maximum voluntary ventilation
  • PCr, phosphocreatine
  • RPE, rating of perceived exertion
  • SGRQ, St George’s Respiratory Questionnaire
  • Tlco, carbon monoxide transfer factor
  • V˙o2, peak oxygen uptake
  • creatine
  • pulmonary rehabilitation
  • chronic obstructive pulmonary disease
  • exercise tolerance
  • fat-free mass
  • quality of life

https://doi.org/10.1136/thx.2004.030452

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • JP Fuld was supported in part by the Wellcome Trust, UK

    • The authors have no conflicts of interest with regard to this manuscript.

    Linked Articles

    • Airwaves
      Airwaves
      Wisia Wedzicha
      Thorax 2005; 60 525-525 Published Online First: 01 Jul 2005.